Literature DB >> 27155865

Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor.

Lihong Liu1, Michael Wen1, Qianqian Zhu1, Jason T Kimata2, Paul Zhou3.   

Abstract

Lipid rafts of the plasma membrane have been shown to be gateways for HIV-1 budding and entry. In nature, many glycosyl-phosphatidylinositol (GPI) anchored proteins are targeted to the lipid rafts. In the present study we constructed two fusion genes, in which C34 peptide or AVF peptide control was genetically linked with a GPI-attachment signal. Recombinant lentiviruses expressing the fusion genes were used to transduce TZM.bl and CEMss-CCR5 cells. Here, we show that with a GPI attachment signal both C34 and AVF are targeted to the lipid rafts through a GPI anchor. GPI-C34, but not GPI-AVF, in transduced TZM.bl cells efficiently blocks the infection of diverse HIV-1 strains of various subtypes. GPI-C34-transduced CEMss-CCR5 cells are totally resistant to HIV-1 infection. Importantly, maximum percentage of inhibition (MPI) by GPI-C34 is comparable to, if not higher than, a very high concentration of soluble C34. Potent blocking by GPI-C34 is likely due to its high local concentration, which allows GPI-C34 to efficiently bind to the prehairpin intermediate and prevent its transition to six helical bundle, thereby interfering with membrane fusion and virus entry. Our findings should have important implications in GPI-anchor-based therapy against HIV-1.

Entities:  

Keywords:  C34 peptide; GPI anchor; Gene delivery; HIV-1; Lipid rafts

Mesh:

Substances:

Year:  2016        PMID: 27155865      PMCID: PMC5577817          DOI: 10.1007/s11481-016-9681-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  42 in total

1.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

2.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry.

Authors:  A D Miller; F Chen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.

Authors:  Lihong Liu; Michael Wen; Weiming Wang; Shumei Wang; Lifei Yang; Yong Liu; Mengran Qian; Linqi Zhang; Yiming Shao; Jason T Kimata; Paul Zhou
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

5.  A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Authors:  Hongxing Hu; Jarrod Voss; Guoliang Zhang; Philippi Buchy; Teng Zuo; Lulan Wang; Feng Wang; Fan Zhou; Guiqing Wang; Cheguo Tsai; Lesley Calder; Steve J Gamblin; Linqi Zhang; Vincent Deubel; Boping Zhou; John J Skehel; Paul Zhou
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

6.  Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Authors:  Jan van Lunzen; Tobias Glaunsinger; Ingrid Stahmer; Volker von Baehr; Christopher Baum; Andrea Schilz; Klaus Kuehlcke; Sonja Naundorf; Holger Martinius; Felix Hermann; Tsanan Giroglou; Sebastian Newrzela; Ingrid Müller; Francis Brauer; Gunda Brandenburg; Alexander Alexandrov; Dorothee von Laer
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

7.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.

Authors:  Lihong Liu; Weiming Wang; Lifei Yang; Huanhuan Ren; Jason T Kimata; Paul Zhou
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

View more
  10 in total

1.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Promoting Global Health - Prevention and Treatment of Substance Abuse and HIV in Asia.

Authors:  Ming D Li; Yih-Ing Hser; Zhiwei Chen; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

3.  Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies.

Authors:  Shuangshuang Wang; Huanhuan Ren; Wenbo Jiang; Honglin Chen; Hongxing Hu; Zhiwei Chen; Paul Zhou
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

4.  Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.

Authors:  Anisha Misra; Emile Gleeson; Weiming Wang; Chaobaihui Ye; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 5.  Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.

Authors:  Alexandra Maslennikova; Dmitriy Mazurov
Journal:  Front Cell Infect Microbiol       Date:  2022-05-25       Impact factor: 6.073

Review 6.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

7.  Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy.

Authors:  Hongliang Jin; Xiaoran Tang; Li Li; Yue Chen; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Cell Mol Immunol       Date:  2021-01-18       Impact factor: 11.530

8.  Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.

Authors:  Yue Chen; Hongliang Jin; Xiaoran Tang; Li Li; Xiuzhu Geng; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

9.  Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.

Authors:  Alexandra Maslennikova; Natalia Kruglova; Svetlana Kalinichenko; Dmitriy Komkov; Mikhail Shepelev; Dmitriy Golubev; Andrei Siniavin; Andrei Vzorov; Alexander Filatov; Dmitriy Mazurov
Journal:  mBio       Date:  2022-01-25       Impact factor: 7.867

Review 10.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.